These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 9552709

  • 1. A short (3-day) course of azithromycin tablets versus a 10-day course of amoxycillin-clavulanic acid (co-amoxiclav) in the treatment of adults with lower respiratory tract infections and effects on long-term outcome.
    Hoepelman IM, Möllers MJ, van Schie MH, Greefhorst AP, Schlösser NJ, Sinninghe Damsté EJ, van de Moosdijk CN, Dalinghaus WH, Eland ME, Mol SJ, Rozenberg-Arska M.
    Int J Antimicrob Agents; 1997 Jan; 9(3):141-6. PubMed ID: 9552709
    [Abstract] [Full Text] [Related]

  • 2. A single-blind comparison of three-day azithromycin and ten-day co-amoxiclav treatment of acute lower respiratory tract infections.
    Hoepelman AI, Sips AP, van Helmond JL, van Barneveld PW, Neve AJ, Zwinkels M, Rozenberg-Arska M, Verhoef J.
    J Antimicrob Chemother; 1993 Jun; 31 Suppl E():147-52. PubMed ID: 8396086
    [Abstract] [Full Text] [Related]

  • 3. Once-daily, 3-day azithromycin versus a three-times-daily, 10-day course of co-amoxiclav in the treatment of adults with lower respiratory tract infections: results of a randomized, double-blind comparative study.
    Gris P.
    J Antimicrob Chemother; 1996 Jun; 37 Suppl C():93-101. PubMed ID: 8818850
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Comparison of azithromycin and co-amoxiclav in the treatment of acute tracheobronchitis and acute infectious exacerbations of chronic bronchitis in adults. Azithromycin Study Group.
    Biebuyck XA.
    J Int Med Res; 1996 Jun; 24(5):407-18. PubMed ID: 8895044
    [Abstract] [Full Text] [Related]

  • 7. Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis.
    Starakis I, Gogos CA, Bassaris H.
    Int J Antimicrob Agents; 2004 Feb; 23(2):129-37. PubMed ID: 15013037
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A multinational, multicentre, non-blinded, randomized study of moxifloxacin oral tablets compared with co-amoxiclav oral tablets in the treatment of acute exacerbation of chronic bronchitis.
    Schaberg T, Ballin I, Huchon G, Bassaris H, Hampel B, Reimnitz P, AECB Study Group.
    J Int Med Res; 2001 Feb; 29(4):314-28. PubMed ID: 11675905
    [Abstract] [Full Text] [Related]

  • 10. A comparison of the efficacy, tolerability and safety of azithromycin and co-amoxiclav in the treatment of sinusitis in adults.
    Clement PA, de Gandt JB.
    J Int Med Res; 1998 Feb; 26(2):66-75. PubMed ID: 9602984
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Randomized, double-blind study of the clinical efficacy of 3 days of azithromycin compared with co-amoxiclav for the treatment of acute otitis media.
    Dunne MW, Latiolais T, Lewis B, Pistorius B, Bottenfield G, Moore WH, Garrett A, Stewart TD, Aoki J, Spiegel C, Boettger D, Shemer A.
    J Antimicrob Chemother; 2003 Sep; 52(3):469-72. PubMed ID: 12888586
    [Abstract] [Full Text] [Related]

  • 13. Azithromycin for acute lower respiratory tract infections.
    Panpanich R, Lerttrakarnnon P, Laopaiboon M.
    Cochrane Database Syst Rev; 2004 Oct 18; (4):CD001954. PubMed ID: 15497172
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Once-daily oral gatifloxacin vs three-times-daily co-amoxiclav in the treatment of patients with community-acquired pneumonia.
    Lode H, Magyar P, Muir JF, Loos U, Kleutgens K, International Gatifloxacin Study Group.
    Clin Microbiol Infect; 2004 Jun 18; 10(6):512-20. PubMed ID: 15191378
    [Abstract] [Full Text] [Related]

  • 16. Azithromycin for acute lower respiratory tract infections.
    Laopaiboon M, Panpanich R, Swa Mya K.
    Cochrane Database Syst Rev; 2015 Mar 08; 2015(3):CD001954. PubMed ID: 25749735
    [Abstract] [Full Text] [Related]

  • 17. The efficacy and safety of oral pharmacokinetically enhanced amoxycillin-clavulanate 2000/125 mg, twice daily, versus oral amoxycillin-clavulanate 1000/125 mg, three times daily, for the treatment of bacterial community-acquired pneumonia in adults.
    Petitpretz P, Chidiac C, Soriano F, Garau J, Stevenson K, Rouffiac E, 556 Clinical Study Group.
    Int J Antimicrob Agents; 2002 Aug 08; 20(2):119-29. PubMed ID: 12297361
    [Abstract] [Full Text] [Related]

  • 18. Azithromycin for acute lower respiratory tract infections.
    Panpanich R, Lerttrakarnnon P, Laopaiboon M.
    Cochrane Database Syst Rev; 2008 Jan 23; (1):CD001954. PubMed ID: 18253999
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.